Beginning in the mid-1950s, the U.S. Army conducted research involving thousands of human subjects on various chemical agents, including LSD, BZ and marijuana derivatives, to assess their utility for chemical warfare applications.
Now one of the leading participants in that enterprise, Dr. James S. Ketchum, has published a memoir entitled “Chemical Warfare: Secrets Almost Forgotten.”
“It is a detailed autobiographical reconstruction of the Edgewood Arsenal program of evaluating possible incapacitating agents in human volunteers (enlisted men) during the 1960s,” he told Secrecy News. “It reveals facts buried in restricted archives for many years and includes a voluminous appendix of research data acquired, much of which has not previously been released to the public.”
The self-published volume is a candid, not entirely flattering, sometimes morbidly amusing account of a little-documented aspect of Army research.
“I had early misgivings that my [manuscript] might raise some red flags in [the Army] Security Office, but was pleasantly surprised when none appeared,” he writes.
Among other things, Dr. Ketchum co-authored the chapter on incapacitating agents in the CBW volume of Textbook of Military Medicine.
“Definitely someone to take seriously,” a colleague of Secrecy News wrote. “Although I expect to disagree with much of his opinion, the historical information will be very useful, much of it not available elsewhere.”
Further background and book order information is available here.
Update, 6/5/19: An obituary for James Ketchum appeared in the Washington Post here.
Our analysis of federal AI governance across administrations shows that divergent compliance procedures and uneven institutional capacity challenge the government’s ability to deploy AI in ways that uphold public trust.
From California to New Jersey, wildfires are taking a toll—costing the United States up to $424 billion annually and displacing tens of thousands of people. Congress needs solutions.
To secure the U.S. bio-infrastructure, maintain global leadership in biotechnology, and safeguard American citizens from emerging threats to their privacy, the federal government must modernize its approach to human genetic and biological data.
To ensure an energy transition that brings broad based economic development, participation, and direct benefits to communities, we need federal policy that helps shape markets. Unfortunately, there is a large gap in understanding of how to leverage federal policy making to support access to capital and credit.